§VHT has signed a five year contract with BreastScreen Queensland for the roll-out of VolparaEnterprise, its quality assurance product. There is potential for additional services to be added. Although no financial details have been released we would expect other state based screening programs will likely follow. §In other news, VHT noted the renewal and extension of a major contract with US Radiology. §The next key catalyst will be the release of the cashflow report in late January which is typically a stronger quarter. §We have made no changes to our forecasts and as a result our valuation and target price remain unchanged at A$1.71. Add recommendation maintained. |